Pharmacist Enhanced Service for Cardiovascular Risk Reduction
Pharmacist Enhanced Service in Primary Care for CArdiovascular Risk Reduction (PxES-CAR2+) Project: A Multi-centre Pragmatic, Step-wedge Cluster Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Selangor
-
Subang Jaya, Selangor, Malaysia, 47500
- Shaun Lee
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with diabetes
- Patients with chronic kidney disease (eGFR <60ml/min/1.73m2)
- Patients with established atherosclerotic vascular disease (via patient health records or selfreport) including cerebrovascular disease (prior stroke or transient ischemic attack), cardiovascular disease (myocardial infarction, acute coronary syndrome, stable angina, or revascularization), or peripheral arterial disease (symptomatic and/or ankle brachial index <0.9)
- Primary prevention patients with multiple risk factors and Framingham risk score >30%
Exclusion Criteria:
- Unwilling to participate/sign consent form
- Unwilling or unable to participate in regular follow-up visits
- Pregnancy
- Undergoing existing medication therapy adherence clinic conducted by the Pharmacy Unit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Enhanced pharmacist service
The advanced care group will be undergo a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA) with the pharmacist
|
Calculation of cardiovascular risk by an online tool for discussion on the CVD risk.
Pharmacist will also provide ducation on cardiovascular risk factors and healthy lifestyle.
Any prescription adaptation(s), and/or recommendations where necessary to meet lipid, blood pressure and glycemic control targets and smoking cessation will be initiated
|
|
Active Comparator: Usual care
Patients in the usual care arm will receive their usual care which they will obtain care from their doctor,nurse and pharmacist where appropriate
|
Participants in the arm will receive their care from their respective nurse, doctor or pharmacists as per usual clinic practice
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in cardiovascular risk scores
Time Frame: 3 months
|
The difference from baseline to 3 months in the estimated cardiovascular risk between advanced care and usual care groups assessed using the Framingham scale
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in cardiovascular risk scores
Time Frame: 6 months
|
The difference from baseline to 6 months in the estimated cardiovascular risk between advanced care and usual care groups assessed using the Framingham scale
|
6 months
|
|
Change in cardiovascular risk scores
Time Frame: 12 months
|
The difference from baseline to 12 months in the estimated cardiovascular risk between advanced care and usual care groups assessed using the Framingham scale
|
12 months
|
|
Change in cardiovascular risk scores
Time Frame: 24 months
|
The difference from baseline to 24 months in the estimated cardiovascular risk between advanced care and usual care groups assessed using the Framingham scale
|
24 months
|
|
Achievement of recommended cholesterol, blood pressure and glycemic control targets
Time Frame: 3 months
|
Number of individual achieving target cholesterol, blood pressure and glycemic control target
|
3 months
|
|
Proportion of patients receiving appropriate medication
Time Frame: 3 months
|
Number of patients receiving appropriate BP, cholesterol and diabetes medication
|
3 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficiency of screening
Time Frame: 3 months
|
Number of high risk patients screened for cardiovascular risk
|
3 months
|
|
Change in participant quality of life
Time Frame: 3 months
|
Change in quality of life assessed using EuroQoL-5D from baseline to end of intervention (range 0-1)
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Shaun Lee, Monash University Malaysia
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- PxES-CAR2+
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.